-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on ArriVent BioPharma, Maintains $45 Price Target

Benzinga·08/13/2026 14:24:31
语音播报
Guggenheim analyst Michael Schmitz reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $45 price target.